Chronic consumption of Annona muricata juice triggers and aggravates cerebral tau phosphorylation in wild-type and MAPT transgenic mice

Journal of Neurochemistry

Volumn 139, Issue 4, 2016, Pages 624-639

  Rottscholl, Robert ^a   Haegele, Marlen ^a   Jainsch, Britta ^a   Xu, Hong ^a,b   Respondek, Gesine ^a,b,c   Höllerhage, Matthias ^a,b,c   Rösler, Thomas W ^a,b   Bony, Emilie ^d   Le Ven, Jessica ^d   Guérineau, Vincent ^e   Schmitz Afonso, Isabelle ^e,f   Champy, Pierre ^d   Oertel, Wolfgang H ^a   Yamada, Elizabeth S ^a,g   Höglinger, Günter U ^a,b,c  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITÉ PARIS SUD   (France)

^e CNRS   (France)

^f UNIVERSITÉ DE ROUEN   (France)

^g FEDERAL UNIVERSITY OF PARÁ   (Brazil)

Author keywords

annonacin; environmental neurotoxin; microtubule associated protein tau; neurodegeneration; R406W; tauopathy

Indexed keywords

3 NITROTYROSINE; ANNONACIN; ASIMILOBINE; ISOQUINOLINE ALKALOID; REACTIVE NITROGEN SPECIES; RETICULINE; SYNAPTOPHYSIN; TAU PROTEIN; MAPT PROTEIN, MOUSE; PLANT EXTRACT;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANNONA MURICATA; ARTICLE; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; FOOD INTAKE; FRUIT JUICE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOREACTIVITY; MALE; MASS SPECTROMETRY; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ADVERSE EFFECTS; ANIMAL; ANNONA; BIOSYNTHESIS; BRAIN; C3H MOUSE; C57BL MOUSE; CELL LINE; DRUG EFFECTS; FRUIT AND VEGETABLE JUICE; GENETICS; HUMAN; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; RANDOMIZATION; TRANSGENIC MOUSE;

ANIMALS; ANNONA; BRAIN; CELL LINE; FRUIT AND VEGETABLE JUICES; HUMANS; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; PHOSPHORYLATION; PLANT EXTRACTS; RANDOM ALLOCATION; TAU PROTEINS;

EID: 84987862331     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13835     Document Type: Article

References (80)

1. Behnam M., Ghorbani F., Shin J., Kim D., Jang H., Nouri N., Sedghi M., Salehi M., Ansari B. and Basiri K. (2015) Homozygous MAPT R406W mutation causing FTDP phenotype: a unique instance of a unique mutation. Gene 570, 150–152.
2. Bermejo A., Figadère B., Zafra-Polo M., Barrachina I., Estornell E. and Cortes D. (2005) Acetogenins from Annonaceae: recent progress in isolation, synthesis and mechanisms of action. Nat. Prod. Rep. 22, 269–303.
3. Bhat N. R. and Thirumangalakudi L. (2013) Increased tau phosphorylation and impaired brain insulin/IGF signaling in mice fed a high fat/high cholesterol diet. J. Alzheimers Dis. 36, 781–789.
4. Bird T. D., Nochlin D., Poorkaj P. et al. (1999) A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L). Brain 122(Pt 4), 741–756.
5. Blair L. J., Frauen H. D., Zhang B. et al. (2015) Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy. Acta Neuropathol. Commun. 3, 8.
6. Bonneau N., Le Ven J., Schmitz-Afonso I., Guérineau V., Bajin ba Ndob I., Baloul L., Lewin G., Laprévote O., Brunelle A., Touboul D. and Champy P. (2012) Annonaceous acetogenins as environmental neurotoxins: Human exposure from edible Annona fruits. Planta Med. 78, DOI: 10.1055/s-0034-1394993.
7. Bonneau N., Schmitz-Afonso I., Brunelle A., Touboul D. and Champy P. (2015) Method development for quantification of the environmental neurotoxin annonacin in Rat plasma by UPLC-MS/MS and application to a pharmacokinetic study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1004, 46–52.
8. Caparros-Lefebvre D. and Elbaz A. (1999) Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Lancet 354, 281–286.
9. Caparros-Lefebvre D., Sergeant N., Lees A., Camuzat A., Daniel S., Lannuzel A., Brice A., Tolosa E., Delacourte A. and Duyckaerts C. (2002) Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. Brain 125, 801–811.
10. Champy P., Höglinger G. U., Féger J. et al. (2004) Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe. J. Neurochem. 88, 63–69.
11. Champy P., Melot A., Guérineau V. et al. (2005) Quantification of acetogenins in Annona muricata linked to atypical parkinsonism in guadeloupe. Mov. Disord. 20, 1629–1633.
12. Champy P., Guérineau V. and Laprévote O. (2009) MALDI-TOF MS profiling of annonaceous acetogenins in Annona muricata products for human consumption. Molecules 14, 5235–5246.
13. Cho J. and Johnson G. V. W. (2003) Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J. Biol. Chem. 278, 187–193.
14. Core Team R. (2011) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna.
15. David D. C., Hauptmann S., Scherping I. et al. (2005) Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J. Biol. Chem. 280, 23802–23814.
16. Derbré S., Roué G., Poupon E., Susin S. A. and Hocquemiller R. (2005) Annonaceous acetogenins: the hydroxyl groups and THF rings are crucial structural elements for targeting the mitochondria, demonstration with the synthesis of fluorescent squamocin analogues. ChemBioChem 6, 979–982.
17. Dougherty C. J., Kubasiak L. A., Frazier D. P., Li H., Xiong W., Bishopric N. H. and Webster K. A. (2004) Mitochondrial signals initiate the activation of c-Jun N-terminal kinase (JNK) by hypoxia-reoxygenation. FASEB J. 18, 1060–1070.
18. Escobar-Khondiker M., Höllerhage M., Muriel M. et al. (2007) Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons. J. Neurosci. 27, 7827–7837.
19. Fitting S., Booze R. M., Hasselrot U. and Mactutus C. F. (2008) Differential long-term neurotoxicity of HIV-1 proteins in the rat hippocampal formation: a design-based stereological study. Hippocampus 18, 135–147.
20. Foster N. L., Wilhelmsen K., Sima A. A., Jones M. Z., D'Amato C. J. and Gilman S. (1997) Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference Participants. Ann. Neurol. 41, 706–715.
21. Gauthier-Kemper A., Weissmann C., Golovyashkina N., Sebö-Lemke Z., Drewes G., Gerke V., Heinisch J. J. and Brandt R. (2011) The frontotemporal dementia mutation R406W blocks tau's interaction with the membrane in an annexin A2-dependent manner. J. Cell Biol. 192, 647–661.
22. Goedert M., Hasegawa M., Jakes R., Lawler S., Cuenda A. and Cohen P. (1997) Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases. FEBS Lett. 409, 57–62.
23. Goedert M., Satumtira S., Jakes R., Smith M.J., Kamibayashi C., White 3.C. and Sontag E. (2000) Reduced binding of protein phosphatase 2A to tau protein with frontotemporal dementia and parkinsonism linked to chromosome 17 mutations. J. Neurochem. 75, 2155–2162.
24. Hasegawa M., Smith M. J. and Goedert M. (1998) Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett. 437, 207–210.
25. Hasrat J. A., Pieters L., De Backer J. P., Vauquelin G. and Vlietinck A. J. (1997) Screening of medicinal plants from Suriname for 5-HT(1A) ligands: bioactive isoquinoline alkaloids from the fruit of Annona muricata. Phytomedicine 4, 133–140.
26. Hattox A. M. and Nelson S. B. (2007) Layer V neurons in mouse cortex projecting to different targets have distinct physiological properties. J. Neurophysiol. 98, 3330–3340.
27. Höglinger G. U., Lannuzel A., Khondiker M. E. et al. (2005) The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J. Neurochem. 95, 930–939.
28. Höllerhage M., Matusch A., Champy P., Lombès A., Ruberg M., Oertel W. H. and Höglinger G. U. (2009) Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies. Exp. Neurol. 220, 133–142.
29. Höllerhage M., Deck R., De Andrade A. et al. (2014) Piericidin A aggravates tau pathology in P301S transgenic mice. PLoS ONE 9, e113557.
30. Hoover B. R., Reed M. N., Su J. et al. (2010) Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68, 1067–1081.
31. Hutton M., Lendon C. L., Rizzu P. et al. (1998) Association of missense and 5’-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702–705.
32. Ikeda M., Shoji M., Kawarai T. et al. (2005) Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice. Am. J. Pathol. 166, 521–531.
33. Ikeuchi T., Kaneko H., Miyashita A. et al. (2008) Mutational analysis in early-onset familial dementia in the Japanese population. The role of PSEN1 and MAPT R406W mutations. Dement. Geriatr. Cogn. Disord. 26, 43–49.
34. Iovino M., Pfisterer U., Holton J. L. et al. (2014) The novel MAPT mutation K298E: mechanisms of mutant tau toxicity, brain pathology and tau expression in induced fibroblast-derived neurons. Acta Neuropathol. 127, 283–295.
35. Kotake Y., Okuda K., Kamizono M., Matsumoto N., Tanahashi T., Hara H., Caparros-Lefebvre D. and Ohta S. (2004) Detection and determination of reticuline and N-methylcoclaurine in the Annonaceae family using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci 806, 75–78.
36. Lannuzel A., Michel P. P., Caparros-Lefebvre D., Abaul J., Hocquemiller R. and Ruberg M. (2002) Toxicity of Annonaceae for dopaminergic neurons: potential role in atypical parkinsonism in Guadeloupe. Mov. Disord. 17, 84–90.
37. Lannuzel A., Michel P. P., Höglinger G. U. et al. (2003) The mitochondrial complex I inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of energy metabolism. Neuroscience 121, 287–296.
38. Lannuzel A., Höglinger G. U., Verhaeghe S. et al. (2007) Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes? Brain 130, 816–827.
39. ® using post-column lithium infusion. J. Mass Spectrom. 47, 1500–1509.
40. Le Ven J., Schmitz-Afonso I., Bonneau N., Cresteil T., Akagah B., Lewin G., Brunelle A., Touboul D. and Champy P. (2012a) In vitro phase I metabolism and approach to the distribution of annonacin, a neurotoxic annonaceous acetogenin. Planta Med. 78, doi: 10.1055/s-0032-1321229.
41. Lebœuf M., Cavé A., Bhaumik P., Mukherjee B. and Mukherjee R. (1980) The phytochemistry of the Annonaceae. Phytochemistry 21, 2783–2813.
42. Lebœuf M., Legueut C., Cavé A., Desconclois J. F., Forgacs P. and Jacquemin H. (1981) Alkaloids of Annonaceae. XXIX. Alkaloids of Annona muricata. Planta Med. 42, 37–44.
43. Lee V. M., Goedert M. and Trojanowski J. Q. (2001) Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121–1159.
44. Li N., Ragheb K., Lawler G., Sturgis J., Rajwa B., Melendez J. A. and Robinson J. P. (2003) Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J. Biol. Chem. 278, 8516–8525.
45. Lindquist S. G., Holm I. E., Schwartz M., Law I., Stokholm J., Batbayli M., Waldemar G. and Nielsen J. E. (2008) Alzheimer disease-like clinical phenotype in a family with FTDP-17 caused by a MAPT R406W mutation. Eur. J. Neurol. 15, 377–385.
46. Lindquist S. G., Schwartz M., Batbayli M., Waldemar G. and Nielsen J. E. (2009) Genetic testing in familial AD and FTD: mutation and phenotype spectrum in a Danish cohort. Clin. Genet. 76, 205–209.
47. Liu J., Timm D. E. and Hurley T. D. (2006) Pyrithiamine as a substrate for thiamine pyrophosphokinase. J. Biol. Chem. 281, 6601–6607.
48. Matsushige A., Kotake Y., Matsunami K., Otsuka H., Ohta S. and Takeda Y. (2012) Annonamine, a new aporphine alkaloid from the leaves of Annona muricata. Chem. Pharm. Bull. (Tokyo) 60, 257–259.
49. Maurya S. K., Mishra J., Abbas S. and Bandyopadhyay S. (2016) Cypermethrin stimulates GSK3β-dependent Aβ and p-tau proteins and cognitive loss in young rats: reduced HB-EGF signaling and downstream neuroinflammation as critical regulators. Mol. Neurobiol. 53, 968–982.
50. Miyasaka T., Morishima-Kawashima M., Ravid R., Heutink P., van Swieten J. C., Nagashima K. and Ihara Y. (2001) Molecular analysis of mutant and wild-type tau deposited in the brain affected by the FTDP-17 R406W mutation. Am. J. Pathol. 158, 373–379.
51. Nagatsu T. (1997) Isoquinoline neurotoxins in the brain and Parkinson's disease. Neurosci. Res. 29, 99–111.
52. Nagatsu T. (2002) Amine-related neurotoxins in Parkinson's disease: past, present, and future. Neurotoxicol. Teratol. 24, 565–569.
53. Oberlies N. H., Croy V. L., Harrison M. L. and McLaughlin J. L. (1997) The Annonaceous acetogenin bullatacin is cytotoxic against multidrug-resistant human mammary adenocarcinoma cells. Cancer Lett. 115, 73–79.
54. Ostojic J., Elfgren C., Passant U., Nilsson K., Gustafson L., Lannfelt L. and Froelich Fabre S. (2004) The tau R406W mutation causes progressive presenile dementia with bitemporal atrophy. Dement. Geriatr. Cogn. Disord. 17, 298–301.
55. Passant U., Ostojic J., Froelich Fabre S., Gustafson L., Lannfelt L., Larsson E., Nilsson K., Rosén I. and Elfgren C. (2004) Familial presenile dementia with bitemporal atrophy. Dement. Geriatr. Cogn. Disord. 17, 287–292.
56. Pérez M., Lim F., Arrasate M. and Avila J. (2000) The FTDP-17-linked mutation R406W abolishes the interaction of phosphorylated tau with microtubules. J. Neurochem. 74, 2583–2589.
57. Petrov D., Pedrós I., Artiach G. et al. (2015) High-fat diet-induced deregulation of hippocampal insulin signaling and mitochondrial homeostasis deficiences contribute to Alzheimer disease pathology in rodents. Biochim. Biophys. Acta 1852, 1687–1699.
58. Potts L. F., Luzzio F. A., Smith S. C., Hetman M., Champy P. and Litvan I. (2012) Annonacin in Asimina triloba fruit: implication for neurotoxicity. Neurotoxicology 33, 53–58.
59. Rademakers R., Dermaut B., Peeters K., Cruts M., Heutink P., Goate A. and Van Broeckhoven C. (2003) Tau (MAPT) mutation Arg406Trp presenting clinically with Alzheimer disease does not share a common founder in Western Europe. Hum. Mutat. 22, 409–411.
60. Ramaswamy S., McBride J. L., Han I., Berry-Kravis E. M., Zhou L., Herzog C. D., Gasmi M., Bartus R. T. and Kordower J. H. (2009) Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease. Neurobiol. Dis. 34, 40–50.
61. Reed L. A., Grabowski T. J., Schmidt M. L. et al. (1997) Autosomal dominant dementia with widespread neurofibrillary tangles. Ann. Neurol. 42, 564–572.
62. Reyes J. F., Geula C., Vana L. and Binder L. I. (2012) Selective tau tyrosine nitration in non-AD tauopathies. Acta Neuropathol. 123, 119–132.
63. Rizzu P., Van Swieten J. C., Joosse M. et al. (1999) High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. Am. J. Hum. Genet. 64, 414–421.
64. Santacruz K., Lewis J., Spires T. et al. (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476–481.
65. Schmidt J., Raith K., Boettcher C. and Zenk M. (2005) Analysis of benzylisoquinoline-type alkaloids by electrospray tandem mass spectrometry and atmospheric pressure photoionization. Eur. J. Mass Spectrom. 11, 325–333.
66. Schmitz C. and Hof P. R. (2000) Recommendations for straightforward and rigorous methods of counting neurons based on a computer simulation approach. J. Chem. Neuroanat. 20, 93–114.
67. Singh A. K., Tiwari M. N., Prakash O. and Singh M. P. (2012) A current review of cypermethrin-induced neurotoxicity and nigrostriatal dopaminergic neurodegeneration. Curr. Neuropharmacol. 10, 64–71.
68. Song L., Lu S. X., Ouyang X. et al. (2015) Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology. Mol. Neurodegener. 10, 14.
69. Spillantini M. G. and Goedert M. (2013) Tau pathology and neurodegeneration. Lancet Neurol. 12, 609–622.
70. Stévigny C., Jiwan J. H., Rozenberg R., de Hoffmann E. and Quetin-Leclercq J. (2004) Key fragmentation patterns of aporphine alkaloids by electrospray ionization with multistage mass spectrometry. Rapid Commun. Mass Spectrom. 18, 523–528.
71. van Swieten J. C., Stevens M., Rosso S. M. et al. (1999) Phenotypic variation in hereditary frontotemporal dementia with tau mutations. Ann. Neurol. 46, 617–626.
72. Tapia-Rojas C., Schüller A., Lindsay C. B., Ureta R. C., Mejías-Reyes C., Hancke J., Melo F. and Inestrosa N. C. (2015) Andrographolide activates the canonical Wnt signalling pathway by a mechanism that implicates the non-ATP competitive inhibition of GSK-3β: autoregulation of GSK-3β in vivo. Biochem. J 466, 415–430.
73. Tatebayashi Y., Miyasaka T., Chui D. et al. (2002) Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc. Natl Acad. Sci. USA 99, 13896–13901.
74. Wittmann C. W., Wszolek M. F., Shulman J. M., Salvaterra P. M., Lewis J., Hutton M. and Feany M. B. (2001) Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293, 711–714.
75. Yamada E. S., Respondek G., Müssner S. et al. (2014) Annonacin, a natural lipophilic mitochondrial complex I inhibitor, increases phosphorylation of tau in the brain of FTDP-17 transgenic mice. Exp. Neurol. 253, 113–125.
76. 2 extraction and simultaneous determination of eight annonaceous acetogenins in Annona genus plant seeds by HPLC-DAD method. J. Pharm. Biomed. Anal. 49, 140–144.
77. Yoshiyama Y., Higuchi M., Zhang B., Huang S., Iwata N., Saido T. C., Maeda J., Suhara T., Trojanowski J. Q. and Lee V. M. (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337–351.
78. Zhang B., Higuchi M., Yoshiyama Y., Ishihara T., Forman M. S., Martinez D., Joyce S., Trojanowski J. Q. and Lee V. M. (2004) Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy. J. Neurosci. 24, 4657–4667.
79. Zhang Y., Shi Q., Shi P., Zhang W. and Cheng Y. (2006) Characterization of isoquinoline alkaloids, diterpenoids and steroids in the Chinese herb Jin-Guo-Lan (Tinospora sagittata and Tinospora capillipes) by high-performance liquid chromatography/electrospray ionization with multistage mass spectrometry. Rapid Commun. Mass Spectrom. 20, 2328–2342.
80. Zhao J., Sun X., Yu Z., Pan X., Gu F., Chen J., Dong W., Zhao L. and Zhong C. (2011) Exposure to pyrithiamine increases β-amyloid accumulation, Tau hyperphosphorylation, and glycogen synthase kinase-3 activity in the brain. Neurotox. Res. 19, 575–583.